Multaq (Dronedarone)

Dronedarone, the active ingredient in Multaq, is a antiarrhythmic presented as a tablet for oral use. It is used to manage atrial fibrillation and atrial flutter in adult patients. GNH USA supplies Multaq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Multaq is an antiarrhythmic medication indicated for rhythm control in atrial arrhythmias. - Atrial fibrillation: helps restore and maintain normal sinus rhythm in patients with paroxysmal or persistent AF. - Atrial flutter: reduces recurrence of flutter episodes and supports rhythm stabilization. - Maintenance of sinus rhythm: used as a long‑term strategy to prevent arrhythmia relapse after cardioversion.

Adverse reactions may occur with dronedarone therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring intermittently. - Fatigue: general tiredness or reduced energy. - Headache: occasional mild headache. - Dizziness: transient light‑headedness. - Elevated liver enzymes: mild, reversible increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Pulmonary toxicity: interstitial lung disease or fibrosis. - Bradycardia: clinically significant slowing of heart rate. - QT prolongation: risk of torsades de pointes. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Thromboembolic events: rare but serious clot formation.

Before initiating dronedarone, clinicians should assess patient suitability and monitor for potential risks. - Contraindication in pregnancy: drug is classified as Category X; avoid use in pregnant women. - Avoid in severe hepatic impairment: may exacerbate liver dysfunction. - Caution in heart failure: can worsen symptoms in NYHA class IV patients. - Monitor electrolytes: maintain potassium and magnesium within normal range. - Regular ECG checks: assess QT interval and heart rate. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Dronedarone interacts with several drug classes that can alter its safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase dronedarone levels and toxicity. - Digoxin: dronedarone raises digoxin concentrations, risking arrhythmia. - Anticoagulants (warfarin, dabigatran): enhanced anticoagulant effect, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive bradycardia; monitor heart rate. - Calcium channel blockers (verapamil, diltiazem): may increase plasma dronedarone. - Statins (simvastatin, atorvastatin): higher risk of myopathy; consider dose reduction.